297.45
-3.06 (-1.02%)
| Previous Close | 300.51 |
| Open | 299.12 |
| Volume | 627,774 |
| Avg. Volume (3M) | 1,096,030 |
| Market Cap | 39,713,316,864 |
| Price / Earnings (TTM) | 74.55 |
| Price / Earnings (Forward) | 32.36 |
| Price / Sales | 9.64 |
| Price / Book | 37.49 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2026 |
| Profit Margin | -11.49% |
| Operating Margin (TTM) | 3.04% |
| Diluted EPS (TTM) | -2.11 |
| Quarterly Revenue Growth (YOY) | 20.20% |
| Total Debt/Equity (MRQ) | 2,358.25% |
| Current Ratio (MRQ) | 3.04 |
| Operating Cash Flow (TTM) | -45.11 M |
| Levered Free Cash Flow (TTM) | 223.09 M |
| Return on Assets (TTM) | -1.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Alnylam Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | 3.0 |
| Price Volatility | 4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 1.20 |
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 3.81% |
| % Held by Institutions | 97.56% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ARBUCKLE STUART A | 298.48 | - | 671 | 200,280 |
| AUSIELLO DENNIS A | 298.48 | - | 671 | 200,280 |
| BRANDICOURT OLIVIER | 298.48 | - | 671 | 200,280 |
| HAMBURG MARGARET A | 298.48 | - | 671 | 200,280 |
| KELLOGG PETER N | 298.48 | - | 671 | 200,280 |
| PYOTT DAVID E I | 298.48 | - | 671 | 200,280 |
| REITAN COLLEEN F | 298.48 | - | 671 | 200,280 |
| SCHULMAN AMY W | 298.48 | - | 838 | 250,126 |
| SIGAL CHARLES ELLIOTT | 298.48 | - | 671 | 200,280 |
| Aggregate Net Quantity | 6,206 | |||
| Aggregate Net Value ($) | 1,852,367 | |||
| Aggregate Avg. Buy ($) | 298.48 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ARBUCKLE STUART A | Director | 20 May 2026 | Acquired (+) | 671 | 298.48 | 200,280 |
| AUSIELLO DENNIS A | Director | 20 May 2026 | Acquired (+) | 671 | 298.48 | 200,280 |
| BRANDICOURT OLIVIER | Director | 20 May 2026 | Acquired (+) | 671 | 298.48 | 200,280 |
| HAMBURG MARGARET A | Director | 20 May 2026 | Acquired (+) | 671 | 298.48 | 200,280 |
| KELLOGG PETER N | Director | 20 May 2026 | Acquired (+) | 671 | 298.48 | 200,280 |
| PYOTT DAVID E I | Director | 20 May 2026 | Acquired (+) | 671 | 298.48 | 200,280 |
| REITAN COLLEEN F | Director | 20 May 2026 | Acquired (+) | 671 | 298.48 | 200,280 |
| SCHULMAN AMY W | Director | 20 May 2026 | Acquired (+) | 838 | 298.48 | 250,126 |
| SIGAL CHARLES ELLIOTT | Director | 20 May 2026 | Acquired (+) | 671 | 298.48 | 200,280 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |